Comparative Pharmacology
Head-to-head clinical analysis: GARAMYCIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GARAMYCIN versus LOTEPREDNOL ETABONATE AND TOBRAMYCIN.
GARAMYCIN vs LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
Loteprednol etabonate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
1-2 drops into affected eye(s) every 4-6 hours; in severe cases, may be given every 1-2 hours initially.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
Loteprednol etabonate: ~2.8 hours (ocular); Tobramycin: ~2-3 hours (systemic, prolonged in renal impairment)
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Loteprednol etabonate: 75% renal, 20% fecal; Tobramycin: >90% renal as unchanged drug via glomerular filtration
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic